Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
作者信息
Lwin May, Holroyd Christopher, Wallis Dinny, Davidson Brian, Goulston Lyndsey, de Graaf Hans, Edwards Christopher J
机构信息
NIHR Clinical Research Facility.
Department of Rheumatology, University Hospital Southampton, Southampton, UK.
出版信息
Rheumatol Adv Pract. 2020 Oct 21;4(2):rkaa061. doi: 10.1093/rap/rkaa061. eCollection 2020.
Abstract
摘要
相似文献
1
Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?对于使用生物性改善病情抗风湿药（bDMARDs）或靶向合成改善病情抗风湿药（tsDMARDs）治疗的炎性风湿性疾病患者，新型冠状病毒肺炎（COVID-19）会增加其住院或死亡风险吗？
Rheumatol Adv Pract. 2020 Oct 21;4(2):rkaa061. doi: 10.1093/rap/rkaa061. eCollection 2020.
2
Proposal for a new nomenclature of disease-modifying antirheumatic drugs.疾病修饰抗风湿药物新命名法建议。
Ann Rheum Dis. 2014 Jan;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317. Epub 2013 Sep 26.
3
Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs).合成、非生物性疾病修饰抗风湿药物（DMARDs）的心血管风险。
Curr Vasc Pharmacol. 2020;18(5):455-462. doi: 10.2174/1570161117666190930113837.
4
A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia.澳大利亚自身免疫性炎性风湿疾病患者疫苗接种的实用方法
Intern Med J. 2017 May;47(5):491-500. doi: 10.1111/imj.13371.
5
Pharmacogenetic of antirheumatic treatments: clinical implications.抗风湿治疗的药物遗传学：临床意义。
Pharmacogenomics J. 2007 Feb;7(1):2-9. doi: 10.1038/sj.tpj.6500396. Epub 2006 May 9.
6
Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.类风湿关节炎生物制剂治疗患者在传统合成改善病情抗风湿药物间转换的经济负担及治疗模式
Clin Ther. 2016 May;38(5):1205-16. doi: 10.1016/j.clinthera.2016.03.013. Epub 2016 Apr 2.
7
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.COVID-19 在接受靶向生物制剂和合成疾病修饰抗风湿药物治疗的成人和儿科风湿性疾病患者队列中的发病率。
Semin Arthritis Rheum. 2020 Aug;50(4):564-570. doi: 10.1016/j.semarthrit.2020.05.001. Epub 2020 May 16.
8
Management of vaccination in rheumatic disease.风湿性疾病的疫苗接种管理。
Best Pract Res Clin Rheumatol. 2018 Dec;32(6):720-734. doi: 10.1016/j.berh.2019.03.006. Epub 2019 Apr 17.
9
Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.HBsAg 阳性的风湿性疾病患者在接受抗肿瘤坏死因子治疗或 DMARDs 治疗时乙型肝炎病毒再激活。
Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154.
10
Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis.抗风湿或抗肿瘤坏死因子药物在强直性脊柱炎中的应用与住院感染风险
Scand J Rheumatol. 2019 Mar;48(2):121-127. doi: 10.1080/03009742.2018.1470253. Epub 2018 Aug 16.
引用本文的文献
1
Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.风湿性疾病中的合并症在 COVID-19 大流行期间需要特别考虑。
Rheumatol Int. 2021 Feb;41(2):243-256. doi: 10.1007/s00296-020-04764-5. Epub 2021 Jan 3.
本文引用的文献
1
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.一系列接受免疫抑制靶向治疗的慢性关节炎患者的 COVID-19 临床病程。
Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2.
Zotero 插件